AmBisome for fungal infections in children with blood cancer
Part of Infections clinical trials.
This study follows children and teens with blood cancers who got a fungal infection while on preventive antifungal medicine. It looks at how well liposomal amphotericin B (AmBisome) works and how safe it is for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 month and 18 years old.
- You have a blood cancer (like leukemia or lymphoma).
- You've been taking a preventive antifungal medicine (triazole or echinocandin) for at least 7 days.
- You developed a new fungal infection despite that prevention.
- You have not used amphotericin B in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests amphotericin B (an antifungal medication) in patients with blood cancers who develop a fungal infection despite already taking antifungal preventive medicine. The study aims to see if this medication can treat these hard-to-treat infections.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
This trial studies how the body processes the antifungal drug liposomal amphotericin B (L-AmB) in patients on ECMO (a heart-lung machine). The goal is to find the right dose for treating invasive fungal infections in ICU patients who need ECMO support.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
This trial tests the safety and effectiveness of a medicine called liposomal amphotericin B for treating serious mold infections in liver transplant recipients. It compares this medicine to another antifungal called voriconazole, and may help find the best way to treat these infections after a liver transplant.
Hear when a new Fungal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.